Division of Hematologic Malignancies

The Lymphoma / Myeloma Group at Thomas Jefferson University provides expert, patient-centered care for individuals with a broad range of hematologic malignancies, including Hodgkin and non-Hodgkin lymphomas, multiple myeloma, and related plasma cell disorders. Our multidisciplinary team combines clinical excellence with a strong educational mission, offering students a high-impact learning environment that bridges science, compassion, and innovation.

Our group is committed to delivering state-of-the-art treatments tailored to each patient’s disease biology, treatment history, and personal goals. We offer:

• Expertise in aggressive and indolent lymphomas, Waldenström macroglobulinemia, multiple myeloma, AL amyloidosis, and other plasma cell dyscrasias
• Cutting-edge therapies including CAR T-cell therapy, bispecific antibodies, autologous stem cell transplantation, and targeted agents
• Access to a wide range of clinical trials, including early-phase and investigator-initiated studies
• Integrated supportive care with a focus on symptom management, survivorship, and quality of life
  Our approach emphasizes multidisciplinary collaboration, ensuring that patients benefit from cohesive care that includes hematology, radiation oncology, pathology, pharmacy, social work, and palliative care. 

The Lymphoma / Myeloma Group serves as a rich educational platform for medical students, residents, and fellows. Students engaged in this rotation or academic track gain invaluable exposure to:

• Complex clinical decision making in lymphoid and plasma cell malignancies
• Diagnostic interpretation of bone marrow biopsies, serum protein electrophoresis, flow cytometry, and molecular panels
• Management of both newly diagnosed and relapsed/refractory disease across inpatient and outpatient settings
• Ethical and communication challenges inherent in discussing prognosis, relapse, and long-term survivorship

Students are encouraged to participate in tumor boards, journal clubs, and interdisciplinary case conferences. With close mentorship from faculty actively involved in clinical trials and translational research, learners are supported in exploring scholarly opportunities, including case reports, research abstracts, and quality improvement projects.

As a member of the Myeloma team at Thomas Jefferson University, Adam Binder, MD specializes in the care of patients with multiple myeloma, amyloidosis, and other plasma cell disorders. His clinical and research efforts are focused on improving health delivery strategies and outcomes for patients with these complex conditions, while also serving as a committed educator to medical students, residents, and fellows.

He is recognized for his patient-centered approach to managing newly diagnosed, relapsed/refractory, and high-risk multiple myeloma. His work integrates the latest developments in immunotherapy, CAR T-cell therapy, bispecific antibodies, and targeted treatments, with a strong emphasis on clinical trials and individualized care. He is particularly interested in quality improvement research and translating novel therapies into practice, ensuring that patients have access to cutting-edge treatments in both academic and community settings. His research involvement includes investigator-initiated trials and collaborations aimed at understanding resistance mechanisms and optimizing treatment sequences. Dr. Binder brings the same dedication to education as he does to patient care. He believes that training future physicians is a critical part of advancing the field and improving outcomes for patients with hematologic malignancies. His teaching philosophy emphasizes clinical reasoning, evidence-based learning, and a deep understanding of both disease biology and patient experience. Residents and Fellows will benefit from the:

• Exposure to a wide range of plasma cell disorders, including complex and rare presentations
• Opportunities to engage in clinical trial design and execution, gaining firsthand experience in translational research
• Participation in multidisciplinary case discussions and treatment planning, helping students understand the nuances of individualized care
• Hands-on learning with diagnostics such as bone marrow interpretation, serum protein electrophoresis, and imaging in myeloma
• A focus on patient communication and long-term care strategies, including survivorship and supportive care

As a respected faculty member in the Lymphoma team at Thomas Jefferson University, S. Onder Alpdogan, MD is an expert in the care and management of Hodgkin and non-Hodgkin lymphomas, multiple myeloma, and related plasma cell disorders. Known for his expertise in both clinical practice and research, Dr. Alpdogon is committed to advancing patient care while nurturing the growth of future oncologists through hands-on teaching and mentorship.

Dr. Alpdogan is passionate about medical education and is deeply engaged in training medical students, residents, and fellows. His teaching focuses on critical thinking, evidence-based decision-making, and the application of innovative treatment strategies in lymphoma and myeloma care. Dr. Alpdogan is dedicated to creating an educational environment where students can:

• Participate in interdisciplinary case discussions, tumor board rounds, and journal clubs, honing their diagnostic and clinical reasoning skills in real-world settings.
• Gain hands-on experience in performing and interpreting bone marrow biopsies, flow cytometry, and molecular testing—building a solid foundation in both diagnostic and therapeutic aspects of lymphoma and myeloma care.
• Contribute to clinical research, including involvement in clinical trials and investigator-initiated studies, exploring novel therapies and improving treatment protocols.

Dr. Alpdogan is dedicated to fostering a supportive and challenging learning environment, where students and trainees can grow both professionally and personally. He encourages their development into well-rounded physicians with the skills to excel in hematology/oncology and make meaningful contributions to the field.

One of the top physician-scientists in oncology, Ubaldo Martinez-Outshoorn, MD  is part of  the Myeloma team  here at Thomas Jefferson University, known for his work at the intersection of translational research, clinical innovation, and academic mentorship. With a background in basic science and immunometabolism, Dr. Martinez-Outshoorn brings a unique, research-driven perspective to the treatment of multiple myeloma and related plasma cell disorders.

His approach to myeloma care is grounded in a deep understanding of disease biology and the mechanisms that drive progression and treatment resistance. His clinical practice is strongly informed by his research, which focuses on the tumor microenvironment, cell metabolism, and immune system interactions in multiple myeloma. He actively works to translate these insights into better therapeutic strategies for patients especially those with refractory disease.

Both his students and patients benefit from care that is not only cutting-edge but also scientifically rigorous, as he often integrates promising new treatments from early-phase clinical trials into individualized care plans. He remains deeply committed to advancing myeloma therapy through novel, biologically targeted interventions.

With his style of practicing, Dr. Martinez-Outshoorn is a natural mentor for students with a strong interest in science, research, and the “why” behind the medicine. He fosters intellectual curiosity and challenges learners to think beyond standard algorithms by integrating concepts from molecular biology, oncologic immunology, and experimental therapeutics into clinical discussions. Because of his style of educating, each student understands how to: 

• Engage in bench-to-bedside thinking, connecting emerging research with real-time clinical decisions
• Contribute to translational research projects, with potential opportunities in lab-based investigation or clinical trial collaboration
• Participate in thoughtful discussions on mechanisms of resistance, drug metabolism, and immune dysregulation in myeloma
• Develop critical thinking skills by exploring how and why therapies work, not just when to use them

Beatrice M. Razzo, MD is a determined multiple myeloma specialist at Thomas Jefferson University, where she is actively involved in both advanced clinical care and academic medicine. As a member of the Myeloma Program and the academic faculty track, Dr. Razzo brings a strong commitment to evidence-based treatment and the education of future physicians.

Dr. Razzo specializes in the diagnosis and management of multiple myeloma, light chain (AL) amyloidosis, and other plasma cell disorders. Her clinical approach emphasizes personalized, compassionate care backed by the most current advances in therapy, including immunotherapies, proteasome inhibitors, monoclonal antibodies, and stem cell transplantation.

She is particularly passionate about helping students and trainees connect scientific discovery with bedside decision-making. She actively involves learners in patient discussions, tumor boards, and clinical trial processes, ensuring they understand both the clinical and research landscape of modern myeloma care.

Michael S. Wysota, MD is an Assistant Professor of Medical Oncology at Thomas Jefferson University, specializing in the diagnosis and treatment of B-cell lymphomas, including Diffuse Large B-Cell Lymphoma (DLBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, and Mantle Cell Lymphoma. He is board-certified in Internal Medicine and Hematology, with advanced training in Hematology/Oncology from Montefiore Medical Center.

He provides comprehensive care for patients with various B-cell lymphomas, employing a multidisciplinary approach to treatment. His clinical practice is informed by the latest advancements in lymphoma therapy, ensuring that patients receive personalized and evidence-based care.

Dr. Wysota's research interests are centered on lymphoid malignancies, particularly B-cell lymphomas. His work includes exploring novel therapeutic targets and understanding the molecular mechanisms underlying these diseases. 

As part of the academic faculty at Jefferson, Dr. Wysota is involved in the education and training of medical students, residents, and fellows. He is committed to fostering the next generation of oncologists by providing mentorship and guidance in both clinical and research settings.